Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug allergy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    212 result(s) found for: Drug allergy. Displaying page 8 of 11.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    EudraCT Number: 2018-001136-21 Sponsor Protocol Number: B7451013 Start Date*: 2018-10-22
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, with M...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) HU (Completed) CZ (Completed) GB (Completed) DE (Completed) PL (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2016-000049-30 Sponsor Protocol Number: RITE-2 Start Date*: 2017-07-26
    Sponsor Name:Medical Enterprises Europe B.V
    Full Title: A multicenter, single-arm study evaluating the efficacy of Synergo radiofrequency-induced thermochemotherapy effect (RITE) with Mitomycin C( Synergo + MMC) in non-muscle invasive bladder cancer (NM...
    Medical condition: Non-Muscle-Invasive Bladder Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002470-46 Sponsor Protocol Number: CIM003JG Start Date*: 2013-12-10
    Sponsor Name:Chugai Pharmaceutical Co. Ltd
    Full Title: A Phase II, randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of CIM331 in atopic dermatitis patients who are inadequately control...
    Medical condition: Atopic dermatitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005288-31 Sponsor Protocol Number: MORF-057-201 Start Date*: 2022-07-04
    Sponsor Name:Morphic Therapeutic, Inc.
    Full Title: A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis
    Medical condition: Moderate to Severe Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004493-25 Sponsor Protocol Number: FFR106080 Start Date*: 2006-01-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg...
    Medical condition: Perennial Allergic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) LV (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003670-40 Sponsor Protocol Number: PAN.1 Start Date*: 2018-04-05
    Sponsor Name:Beatrix Children's Hospital, University Medical Center Groningen
    Full Title: Pediatric Ards Neuromuscular blockade (PAN) study: Life-threatening acute respiratory failure in children: to breathe or not to breathe spontaneously, that's the question.
    Medical condition: Pediatric Acute Respiratory Distress Syndrome necessitating mechanical ventilation
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006562-15 Sponsor Protocol Number: FFU111439 Start Date*: 2008-03-28
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110m...
    Medical condition: Perennial Allergic Rhinitis (PAR) in adults and children of 12 years and older.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) HU (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003594-99 Sponsor Protocol Number: 2013RC09 Start Date*: 2013-11-27
    Sponsor Name:Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside
    Full Title: Proof of Concept Evaluation of Drug-Device Interaction with aclidinium bromide via Genuair® and tiotropium bromide via HandiHaler® in COPD using Impulse Oscillometry
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001634-26 Sponsor Protocol Number: RPH001BEV01 Start Date*: 2017-06-07
    Sponsor Name:TRPHARM
    Full Title: Phase I, Double Blind, Randomized, Parallel-Arm, Single-Dose, Pharmacokinetic and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator (Avastin®, Roche) in Healthy Mal...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2015-001259-63 Sponsor Protocol Number: Pollenvaccine2014-01-15 Start Date*: 2016-03-09
    Sponsor Name:Department of Clinical Science, Intervention and Technology, Karolinska Institute
    Full Title: Intralymphatic immunotherapy in increasing doses up to 10 000 SQ-U -a human randomized clinical trial
    Medical condition: Patients with severe to moderate Allegic rhinitis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002869-34 Sponsor Protocol Number: AT-03A-001 Start Date*: 2020-08-11
    Sponsor Name:Atea Pharmaceuticals, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects with Moderate COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000783-29 Sponsor Protocol Number: GBR830-204 Start Date*: 2018-12-18
    Sponsor Name:Ichnos Sciences SA
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects with Moderate to Severe Atopic Dermatitis.
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003666-13 Sponsor Protocol Number: VAC89220HPX3002 Start Date*: 2019-10-15
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1...
    Medical condition: Prevention of HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Restarted) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002567-99 Sponsor Protocol Number: GRC17536-202 Start Date*: 2012-10-01
    Sponsor Name:Glenmark Pharmaceuticals SA
    Full Title: An integrated Phase I/IIa study to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of inhaled GRC 17536 in healthy adult volunteers and multiple ascending doses in ...
    Medical condition: Respiratory conditions such as mild asthma.
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005169-41 Sponsor Protocol Number: SL-372A Start Date*: 2023-03-16
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II-III study to assess efficacy and safety of sublingual immunotherapy in patients suffering from house dust mite allergy
    Medical condition: Patients with house dust mites related allergic rhinitis/rhinoconjunctivitis and well-controlled mild-to-moderate or without asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001610-19 Sponsor Protocol Number: SC-332A Start Date*: 2023-02-27
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy
    Medical condition: Patients with house dust mite-related allergic rhinitis/rhino-conjunctivitis and with well-controlled mild-to-moderate or without asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001587-97 Sponsor Protocol Number: SC-322A Start Date*: 2023-04-06
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy
    Medical condition: Patients with birch pollen-related allergic rhinitis/rhinoconjunctivitis and with well-controlled mild-to-moderate or without asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005226-21 Sponsor Protocol Number: ARD12181 Start Date*: 2012-03-12
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a Current Diagnosis of Intermediate-2 or High-Risk Primary Myelofibrosis,...
    Medical condition: Hematopoietic neoplasm
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10018864 Haematopoietic neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) AT (Completed) ES (Prematurely Ended) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022656-22 Sponsor Protocol Number: A7471009 Start Date*: 2011-09-13
    Sponsor Name:Pfizer, S.L.U.
    Full Title: A randomized double blind phase 3 efficacy and safety study of PF-00299804 versus erlotinib for the treatment of advanced non-small cell lung cancer following progression after, or intolerance to, ...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) SK (Completed) PL (Completed) HU (Completed) IE (Completed) FI (Completed) BE (Completed) GB (Completed) DE (Completed) AT (Completed) DK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-004290-97 Sponsor Protocol Number: ACCILTRA1 Start Date*: 2008-12-19
    Sponsor Name:Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy
    Full Title: A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzle...
    Medical condition: The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 00:54:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA